Accurate determination of residual cancer status after nCRT for

Characteristics of Calcitriol included studiesModality, outcomeStudyCountryData acquisitionNo. includedNo. excludedSexM/FAge, mean, ± SD [range], yTumor type (AC/SCC/other)Tumor stageType of CRTCriteria negative index testCRT-surgery intervalTiming of index testEndoscopic bx, ypT+ onlyKim49KoreaProsp944487/7NR ± NR [NR]92/1/1I-III5-FU + cis and 48 GyBx: no carcinoma4-5 wk3-4 wk after CRT, 1-2 wk before surgeryShaukat50USARetro30025/550 ± NR [36-79]27/3/00-IVNSBx: no carcinomaNR3-6 wk after CRT, 3-6 wk before surgeryYang9USARetro18311861/460 ± 9.4 [32-78]57/6/2II-III5-FU + cis + pac and 40-45 GyBx: no carcinoma4-6 wk<4.3 wk before surgeryPeng51USARetro67057/1063 ± 11 [28-90]67/0/0II-III5-FU + cis + pac and 50.4 GyBx: no carcinomaNR4-6 wk after CRTSarkaria16USARetro443287126/3061 ± NR [NR]117/39/0II-IIICis-based and 50.4 GyBx: no carcinomaMedian 9.4 wkNRMiyata14JapanRetro1230107/1661 ± NR [NR]0/123/0II-IIICis + 5-FU and 40 GyBx: no carcinoma4-6 wk<1 wk after CRTAjani7USARetro3220282/40NR ± NR [23-81]302/20/0I-IIIFluor + plat/tax, and 45-50.4 GyBx: no carcinoma5-6 wkNROwaki22JapanRetro38533/061 ± 8.2 [NR]0/33/0I-IIICis + 5-FU and 40 GyBx: no carcinoma5-7 wk≤1.4 wk before surgeryMolena15USARetro116071/4560 ± 9.6 [NR]0/116/0II-IIICis and 50.4 GyBx: no carcinomaMean 9.0 wk, SD 4.2NRChao26JapanRetro2270222/556 ± 9.1 [NR]0/227/0II-IV5-FU + cis and 30 GyBx: no carcinomaNR4-6 wk after CRTEUS, ypT+ onlyGiovannini53FranceNR32028/454 ± NR [38-70]7/25/0I-IIICis + 5-FU and 30 GyyuT0Mean 3 wk [1.7-5]2 wk after CRTCerfolio48USAProsp671941/768 ± NR [48-76]43/5/0II-IVCis and RT (NS)yuT0NRMedian 3.9 wk after CRTEUS, ypN+ onlyAgarwal47USARetro97088/958 ± NR [32-74]84/13/0I-IIICis and/or tax + 5-FU (+ CPT-11) and 45 GyypN0 (size <5 mm)4-6 wkNREloubeidi23USARetro20735148/2461 ± NR [30-88]131/15/5I-IIIChemotherapy (NS) and 50.4 GyyuN0 (size <1 cm)NRNREndoscopic bx and EUS, ypT+Schneider17GermanyProsp9111 + 14 and11 + 1074/1759 ± NR [21-74]31/49/0I-IIICis + 5-FU and 36 GyBx: no carcinoma and yuT02.3-4.4 wk2-3 wk after CRT, 0.3-1.4 wk before surgeryEUS, ypT+ and EUS, ypN+Dittler52GermanyNR180NRNR0/18/0II-III5-FU (+ cis + leuc + eto) and 30 or 40 GyyuT0 and yuN0 (size NR)NRNRBowrey29USANR17310/760 ± NR [47-72]10/7/0II-IIICis + 5-FU and 40 GyyuT0 and yuN0 (size <6 mm)NR<2 wk after CRTLaterza54ItalyProsp11138NRNR0/73/0I-IIICis + 5-FU and 30 GyyuT0 and yuN0 (size NR)Mean 3.6 wk2 wk after CRTZuccaro55USARetro7213NR60 ± NR [30-77]41/18/0I-IIICis + 5-FU and 45 GyyuT0 and yuN0 (size <1 cm)4-6 wk4 wk after CRTWillis56USARetro41032/961 ± NR [29-76]28/12/1I-IIICis (or car) + 5-FU and ≥30 GyyuT0 and ypN0 (size NR)Median 3.7 wk [0-10.4]Median 1.9 wk [0-5.9] after CRT, median 1.9 wk [0-4.6] before surgeryGriffin19USARetro1043164/962 ± NR [40-79]66/7/0II-IIIPlat and 45-50 GyyuT0 and ypN0 (size NR)NR4-6 wk after CRT, 3.1 image wk [0.3-11.1] before surgeryYen21TaiwanRetro566476 + 786/456 ± NR [34-88]0/83/0II-IVCis + 5-FU or pac (+ Cet or leuc + 5-FU) and 40 GyyuT0 and yuN0 (size <5 mm)NRMean 2.7 wk before surgeryEndoscopic bx and EUS, ypT+ and EUS, ypN+Kalha20USARetro83077/659 ± NR [NR]83/0/0IIa-IIICis + 5-FU + pac + CPT-11 and 45 GyBx: no carcinoma and yuT0 and yuN0 (size <1 cm)>1.4 wk>1.4 wks after CRT, <2 wk before surgeryM, Male; F, female; SD, standard deviation; AC, adenocarcinoma; SCC, squamous cell carcinoma; CRT, chemoradiotherapy; Bx, biopsy; ypT+, ; prosp, prospective; NR, not reported; 5-FU, 5-fluorouracil; Cis, cisplatin; retro, retrospective; NS, not specified; pac, paclitaxel; fluor, fluoropyrimidine; plat, platinum; tax, taxol; yuT0, ultrasonographic complete response of primary tumor; yuN0, ultrasonographic absence of residual lymph node involvement; ypN+, pathologic residual lymph node involvement; ypN0, pathologic absence of residual lymph node in
Sign In or Register to comment.